Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study
ROC curve analyses for the use of BST2, CEA, and the two-marker panel in discriminating CRC patients from healthy controls. (a) Analysis using all stage CRC patients () and healthy controls (). (b) Analysis using stages I-II CRC patients () from healthy controls (). (c) The distributions of plasma levels of BST2 and CEA among the 120 CRC patients and 120 healthy controls (CEA-BST2 plot).